Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MixIstar
- Development stage
- Unknown
- Lead developer
- Halex Istar
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
MixIstar is an intravenous maintenance and rehydration solution developed by Halex Istar. It is a fixed-dose combination containing potassium chloride, sodium chloride, and glucose. The solution is indicated for the maintenance and restoration of normal body fluid volume and electrolyte composition, providing a source of water, essential electrolytes (sodium, potassium, and chloride), and calories (from glucose) to prevent ketosis and protein degradation. MixIstar is approved in Brazil and is available in various concentrations of sodium chloride (0.4%, 0.6%, and 0.8%) to meet individual patient hydration and electrolyte requirements.
- Brand names
- MixIstar
- Other names
- cloreto de potássio + cloreto de sódio + glicosepotassium chloride + sodium chloride + glucosepotassium chloride + sodium chloride + glucose solution
Beyond the preview
Go deeper on MixIstar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MixIstar.